drugset / Trial / NCT04883125
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Assessment of patients response and expression levels of CITED2 and HIF2a genes on adding pioglitazone to imatinib therapy.
Timeline
- Start
- 2018-01-01
- Primary completion
- 2021-04-15
- Completion
- 2021-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pioglitazone | Small molecule | 15 mg | — |
| Comparator | Imatinib | Small molecule | 400 mg | — |